Evidence map›Paper›PMID 29910040›Full record

Trial reportLancet (London, England)2018

Sodium bicarbonate therapy for patients with severe metabolic acidaemia in the intensive care unit (BICAR-ICU): a multicentre, open-label, randomised controlled, phase 3 trial.

Samir Jaber, Catherine Paugam, Emmanuel Futier, Jean-Yves Lefrant, Sigismond Lasocki, Thomas Lescot, Julien Pottecher, Alexandre Demoule, Martine Ferrandière, Karim Asehnoune and 15 more

Erratum issued Registry-linked trialOpen access · greenAbstract readClinical Trial, Phase IIIMulticenter Study
PubMed Publisher
In one paragraph

Trial report in Lancet (London, England), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT02476253 (Sodium Bicarbonate to Treat Severe Acidosis in the Critically Ill), which is not on this map. Cited by 164 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
164citing papers in PubMed, 11 pooled it
24.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02476253 phase3completednot on this map

Sodium Bicarbonate to Treat Severe Acidosis in the Critically Ill : A Multiple Center Randomized Clinical Trial (BICAR-ICU)

TypeinterventionalSponsorUniversity Hospital, MontpellierRan2015 to 2017Enrolled400ConditionsMetabolic AcidosisArmsSodium Bicarbonate
3 · Its place in the literature

Who cites it

164 citing papers in PubMed, 11 syntheses or guidelines pooled it, 367 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. [S3 guideline on sepsis-prevention, diagnosis, therapy, and follow-up care-update 2025].Medizinische Klinik, Intensivmedizin und Notfallmedizin · 2025
    Guideline
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Sodium bicarbonate therapy for metabolic acidosis in critically ill patients: a survey of Australian and New Zealand intensive care clinicians.Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine · 2020
    Trial
  19. Sodium bicarbonate in 5% dextrose: can clinicians tell the difference?Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine · 2020
    Trial
  20. Article

104 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

25 authors at 9 institutions in 1 country.

Samir JaberSaint Eloi ICU, Montpellier University Hospital, PhyMedExp, INSERM, CNRS, Montpellier, France. Electronic address: s-jaber@chu-montpellier.fr.
Catherine PaugamAP-HP, Département Anesthésie et Réanimation, Hôpital Beaujon, Hôpitaux Universitaires Paris Nord Val de Seine, Paris, France.
Emmanuel FutierCHU de Clermont-Ferrand, Department of Perioperative Medicine, GReD, UMR/CNRS6293, University Clermont Auvergne, INSERM U1103, Clermont-Ferrand, France.
Jean-Yves LefrantCHU de Nîmes, Département Anesthésie et Réanimation, University of Montpellier-Nîmes, Nîmes, France.
Sigismond LasockiCHU d'Angers, Réanimation Chirurgicale, Angers, France.
Thomas LescotAP-HP, Département Anesthésie et Réanimation, Hôpital Saint Antoine, Paris, France.
Julien PottecherHôpitaux Universitaires de Strasbourg, Service d'Anesthésie-Réanimation Chirurgicale-Université de Strasbourg, Fédération de Médecine Translationnelle de Strasbourg, Strasbourg, France.
Alexandre DemouleService de Pneumologie, Sorbonne Université, INSERM, UMRS1158 Neurophysiologie Respiratoire Expérimentale et Clinique, Paris, France; AP-HP, Groupe Hospitalier Pitié-Salpêtrière Charles Foix, Service de Pneumologie et Réanimation Médicale du Département R3S, Paris, France.
Martine FerrandièreCHU de Tours, Réanimation Chirurgicale, Tours, France.
Karim AsehnouneCHU de Nantes, Département Anesthésie et Réanimation Chirurgicale, Nantes, France.
Jean DellamonicaCHU de Nice, Département de Réanimation Médicale, INSERM-C3M-Université Cote d'Azur, Nice, France.
Lionel VellyAix-Marseille Université, AP-HM, Département Anesthésie et Réanimation Chirurgicale, Groupe Hospitalier Timone, UMR 7289, CNRS, Marseille, France.
Paër-Sélim AbbackAP-HP, Département Anesthésie et Réanimation, Hôpital Beaujon, Hôpitaux Universitaires Paris Nord Val de Seine, Paris, France.
Audrey de JongSaint Eloi ICU, Montpellier University Hospital, PhyMedExp, INSERM, CNRS, Montpellier, France.
Vincent BrunotDépartement de Médecine Intensive et Réanimation, Montpellier University Hospital, PhyMedExp, INSERM, CNRS, Montpellier, France.
Fouad BelafiaSaint Eloi ICU, Montpellier University Hospital, PhyMedExp, INSERM, CNRS, Montpellier, France.
Antoine RoquillyCHU de Nantes, Département Anesthésie et Réanimation Chirurgicale, Nantes, France.
Gérald ChanquesSaint Eloi ICU, Montpellier University Hospital, PhyMedExp, INSERM, CNRS, Montpellier, France.
Laurent MullerCHU de Nîmes, Département Anesthésie et Réanimation, University of Montpellier-Nîmes, Nîmes, France.
Jean-Michel ConstantinCHU de Clermont-Ferrand, Department of Perioperative Medicine, GReD, UMR/CNRS6293, University Clermont Auvergne, INSERM U1103, Clermont-Ferrand, France.
Helena BertetCHU de Montpellier, Department of Statistics, Montpellier University, Montpellier, France.
Kada KloucheDépartement de Médecine Intensive et Réanimation, Montpellier University Hospital, PhyMedExp, INSERM, CNRS, Montpellier, France.
Nicolas MolinariCHU de Montpellier, Department of Statistics, Montpellier University, Montpellier, France.
Boris JungDépartement de Médecine Intensive et Réanimation, Montpellier University Hospital, PhyMedExp, INSERM, CNRS, Montpellier, France.
BICAR-ICU Study Group
Centre National de la Recherche Scientifique · FRUniversité de Montpellier · FRCentre Hospitalier Universitaire de Nantes · FRInserm · FRHôpital Beaujon · FRSorbonne Université · FRCentre Hospitalier Universitaire d'Angers · FRCentre Hospitalier Universitaire de Tours · FRHôpitaux Universitaires de Strasbourg · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAcute acidaemia is frequently observed during critical illness. Sodium bicarbonate infusion for the treatment of severe metabolic acidaemia is a possible treatment option but remains controversial, as no studies to date have examined its effect on clinical outcomes. Therefore, we aimed to evaluate whether sodium bicarbonate infusion would improve these outcomes in critically ill patients.

methodsWe did a multicentre, open-label, randomised controlled, phase 3 trial. Local investigators screened eligible patients from 26 intensive care units (ICUs) in France. We included adult patients (aged ≥18 years) who were admitted within 48 h to the ICU with severe acidaemia (pH ≤7·20, PaCO

findingsBetween May 5, 2015, and May 7, 2017, we enrolled 389 patients into the intention-to-treat analysis in the overall population (194 in the control group and 195 in the bicarbonate group). The primary outcome occurred in 138 (71%) of 194 patients in the control group and 128 (66%) of 195 in the bicarbonate group (absolute difference estimate -5·5%, 95% CI -15·2 to 4·2; p=0·24). The Kaplan-Meier method estimate of the probability of survival at day 28 between the control group and bicarbonate group was not significant (46% [95% CI 40-54] vs 55% [49-63]; p=0·09. In the prespecified AKIN stratum of patients with a score of 2 or 3, the Kaplan-Meier method estimate of survival by day 28 between the control group and bicarbonate group was significant (37% [95% CI 28-48] vs 54% [45-65]; p=0·0283). [corrected] Metabolic alkalosis, hypernatraemia, and hypocalcaemia were observed more frequently in the bicarbonate group than in the control group, with no life-threatening complications reported.

interpretationIn patients with severe metabolic acidaemia, sodium bicarbonate had no effect on the primary composite outcome. However, sodium bicarbonate decreased the primary composite outcome and day 28 mortality in the a-priori defined stratum of patients with acute kidney injury.

fundingFrench Ministry of Health and the Société Française d'Anesthésie Réanimation.

Indexed as

Intensive Care UnitsAcidosisCohort StudiesHumansHydrogen-Ion ConcentrationInfusions, IntravenousRenal Replacement TherapySodium BicarbonateSurvival AnalysisSodium Bicarbonate

Identifiers

PMID29910040
OpenAlexW2807966166

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.